OBICETRAPIB AS A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR: A CLINICAL AND PHARMACOLOGICAL REVIEW AND PROSPECTS FOR USE (LITERATURE REVIEW)
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Cardiovascular diseases remain the leading cause of mortality worldwide, and dyslipidemia is one of the key factors in their development.Despite the availability of effective lipid-lowering agents, a substantial proportion of patients with high and very high cardiovascular risk fail to achieve target low-density lipoprotein (LDL) cholesterol levels, resulting in the persistence of residual risk.In this context, the search for new pharmacological targets remains relevant.One promising approach is the inhibition of cholesteryl ester transfer protein (CETP), particularly through the use of obicetrapib, a next-generation selective CETP inhibitor.The aim of this study was to summarize and critically analyze current experimental and clinical data regarding the pharmacological properties of obicetrapib, its effects on the lipid profile, efficacy, and safety based on phase II-III trials, as well as to determine its place in contemporary lipid-lowering therapy strategies.A systematic review of international scientific sources addressing the biological role of CETP, mechanisms of action of its inhibitors, and the clinical application of obicetrapib was conducted.Methods of analysis, synthesis, and generalization were employed to assess the drug's effects on lipid metabolism parameters, as well as its efficacy and safety.In phase II-III clinical trials, obicetrapib demonstrated significant reductions in LDL, apolipoprotein B, and lipoprotein(a), along with an increase in high-density lipoprotein (HDL) cholesterol.In the BROADWAY and TANDEM studies, the drug was effective both as monotherapy and in combination with ezetimibe in high-risk patients.The safety profile remained favorable, with no adverse effects on blood pressure or hormonal parameters.Thus, obicetrapib may be considered a promising agent for intensive correction of dyslipidemia and reduction of residual cardiovascular risk.
Fields of Study & Subjects
Lipoproteins and Cardiovascular Health
Cholesterol and Lipid Metabolism
Lipid metabolism and disorders
Publication details
- Journal / source
- Bulletin of Problems Biology and Medicine
- Volume
- 1
- Issue
- 1
- Pages
- 61–61
- Publication date
- 1 January 2026
- Language
- EN